Oryzon Genomics SA Revenue and Competitors
Estimated Revenue & Valuation
- Oryzon Genomics SA's estimated annual revenue is currently $10.4M per year.
- Oryzon Genomics SA's estimated revenue per employee is $155,000
Employee Data
- Oryzon Genomics SA has 67 Employees.
- Oryzon Genomics SA grew their employee count by -7% last year.
Oryzon Genomics SA's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Medical Officer, CNS Clinical Development | Reveal Email/Phone |
3 | Chief Clinical Operations | Reveal Email/Phone |
4 | COO, CFO | Reveal Email/Phone |
5 | Chief Intellectual Property Officer | Reveal Email/Phone |
6 | Global Chief Medical Officer | Reveal Email/Phone |
7 | VP the Board Directors | Reveal Email/Phone |
8 | Subdirector Financiero (Deputy Financial Manager - DFM) | Reveal Email/Phone |
9 | CMC Director | Reveal Email/Phone |
10 | Director Business Development & Licensing (BDO) | Reveal Email/Phone |
Oryzon Genomics SA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.8M | 76 | 21% | N/A | N/A |
#2 | $10.5M | 68 | 19% | N/A | N/A |
#3 | $10.4M | 67 | -7% | N/A | N/A |
#4 | $7.4M | 48 | 12% | N/A | N/A |
#5 | $9.1M | 59 | 23% | $10.9M | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 33% | $6.78M | N/A |
#8 | $5.9M | 38 | 15% | $6.87M | N/A |
#9 | $1.1M | 7 | -36% | N/A | N/A |
What Is Oryzon Genomics SA?
Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.\nOryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases.\nOryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.\nThe company was founded in 2000 and has offices in Spain and the United States.
keywords:N/A
N/A
Total Funding
67
Number of Employees
$10.4M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cornellà de Llobregat
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.7M | 67 | 76% | N/A |
#2 | N/A | 69 | 44% | N/A |
#3 | N/A | 69 | 15% | N/A |
#4 | N/A | 72 | 26% | N/A |
#5 | $9M | 90 | 5% | N/A |